Prevention of Cardiovascular Disease in Women

Abstract Cardiovascular disease is the leading cause of death among women. In fact, the cardiovascular disease mortality rate among women exceeds the rate in men. Unfortunately, many minority women are still unaware of the importance of this disease. All women, including those with no history of cardiovascular disease, should have an accurate estimate of the probability of a cardiovascular disease event (death, myocardial infarction, or stroke) usually within the next decade. Such an estimate will help determine if women are candidates for preventive measures and specific therapies such as aspirin. Data from the Framingham Heart Study were used to construct a risk score, which is now widely used; however, other risk scores are available. To prevent cardiovascular disease, women should refrain from smoking, maintain a healthy weight, eat a heart-healthy diet, be physically active, and have normal blood pressure and cholesterol levels. Aspirin can be considered for primary prevention, with expected benefit to prevent ischemic stroke; however, this needs to be balanced against potential bleeding risk. Hormone therapy is no longer recommended due to an increase in adverse events (most consistently seen as increased ischemic stroke risk). Folic acid is also no longer recommended due to lack of benefit.

[1]  A. Bavry,et al.  Aspirin: Its risks, benefits, and optimal use in preventing cardiovascular events , 2013, Cleveland Clinic Journal of Medicine.

[2]  Dolores Corella,et al.  Primary prevention of cardiovascular disease with a Mediterranean diet. , 2013, The New England journal of medicine.

[3]  L. Mosca,et al.  Fifteen-Year Trends in Awareness of Heart Disease in Women: Results of a 2012 American Heart Association National Survey , 2013, Circulation.

[4]  V. Moyer Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: U.S. Preventive Services Task Force Recommendation Statement , 2013, Annals of Internal Medicine.

[5]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[6]  M. Ory,et al.  Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women. , 2012, Journal of women's health.

[7]  E. Boerwinkle,et al.  Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. , 2012, American journal of hypertension.

[8]  J. Manson,et al.  Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. , 2012, Archives of internal medicine.

[9]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.

[10]  Rowena J Dolor,et al.  Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. , 2011, Journal of the American College of Cardiology.

[11]  J. Jukema,et al.  Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. , 2010, Archives of internal medicine.

[12]  Jennifer G. Robinson,et al.  Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. , 2010, Journal of the American College of Cardiology.

[13]  R. V. van Dam,et al.  Long‐term effectiveness of diet‐plus‐exercise interventions vs. diet‐only interventions for weight loss: a meta‐analysis , 2009, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[14]  U. P. S. T. Force Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement , 2009, Annals of Internal Medicine.

[15]  J. Manson,et al.  Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. , 2008, JAMA.

[16]  Simon Capewell,et al.  Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. , 2007, The New England journal of medicine.

[17]  Rowena J Dolor,et al.  Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. , 2007, Journal of the American College of Cardiology.

[18]  N. Cook,et al.  Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.

[19]  J. Buring,et al.  Effects of Conjugated Equine Estrogen on Stroke in the Women’s Health Initiative , 2006, Circulation.

[20]  J. Manson,et al.  Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. , 2006, JAMA.

[21]  V. Fuster,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[22]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[23]  Eric J Topol,et al.  Prevalence of conventional risk factors in patients with coronary heart disease. , 2003, JAMA.

[24]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[25]  C. Kooperberg,et al.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. , 2003, JAMA.

[26]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[27]  J. Manson,et al.  Walking compared with vigorous exercise for the prevention of cardiovascular events in women. , 2002, The New England journal of medicine.

[28]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[29]  W. Mack,et al.  Antiatherosclerosis interventions in women. , 2002, The American journal of cardiology.

[30]  S. Grundy,et al.  Prevention Conference VI: Diabetes and Cardiovascular Disease: Executive Summary Conference Proceeding for Healthcare Professionals From a Special Writing Group of the American Heart Association , 2002, Circulation.

[31]  J. Manson,et al.  Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. , 2002, JAMA.

[32]  M. Marmot,et al.  Psychological distress as a risk factor for coronary heart disease in the Whitehall II Study. , 2002, International journal of epidemiology.

[33]  R. Robertson Women and cardiovascular disease: the risks of misperception and the need for action. , 2001, Circulation.

[34]  A. LaCroix,et al.  Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. , 2001, JAMA.

[35]  F. Speizer,et al.  A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease , 2000, Annals of Internal Medicine.

[36]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[37]  R. Naoumova,et al.  Novel lipid-regulating drugs , 2000, Expert opinion on investigational drugs.

[38]  J W Erdman,et al.  AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. , 2000, Circulation.

[39]  S M Grundy,et al.  Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 1999, Circulation.

[40]  S. Grundy,et al.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.

[41]  M. de Lorgeril,et al.  Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. , 1999, Circulation.

[42]  S. Oparil,et al.  Guide to Preventive Cardiology for Women , 1999 .

[43]  Wenger Nk Addressing coronary heart disease risk in women. , 1998 .

[44]  Ronald M. Krauss,et al.  American Heart Association Call to Action: Obesity as a Major Risk Factor for Coronary Heart Disease , 1998 .

[45]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[46]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[47]  G. Smith,et al.  Meta-analysis Spurious precision? Meta-analysis of observational studies , 1998, BMJ.

[48]  O. Faergeman,et al.  Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) , 1997, Circulation.

[49]  J. Manson,et al.  Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. , 1997, Circulation.

[50]  J. Witteman,et al.  Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.

[51]  T. Bush Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. , 1996, European heart journal.

[52]  S. Ingles,et al.  Leisure, home, and occupational physical activity and cardiovascular risk factors in postmenopausal women. The Postmenopausal Estrogens/Progestins Intervention (PEPI) Study. , 1996, Archives of internal medicine.

[53]  D. Rader,et al.  A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia , 1995, Nature Medicine.

[54]  C. Rackley Estrogen and coronary artery disease in postmenopausal women. , 1995, The American journal of medicine.

[55]  J. Manson,et al.  The primary prevention of coronary heart disease in women. , 1995, The New England journal of medicine.

[56]  K. Patrick,et al.  Physical Activity and Public Health: A Recommendation From the Centers for Disease Control and Prevention and the American College of Sports Medicine , 1995 .

[57]  J. Manson Postmenopausal hormone therapy and atherosclerotic disease. , 1994, American heart journal.

[58]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[59]  A. Reunanen,et al.  Antioxidant vitamin intake and coronary mortality in a longitudinal population study. , 1994, American journal of epidemiology.

[60]  W. Willett,et al.  Smoking Cessation in Relation to Total Mortality Rates in Women: A Prospective Cohort Study , 1993, Annals of Internal Medicine.

[61]  J. Cleeman,et al.  Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. , 1993, JAMA.

[62]  W. Castelli Epidemiology of triglycerides: a view from Framingham. , 1992, The American journal of cardiology.

[63]  A. Bostom,et al.  Postmenopausal estrogen therapy and cardiovascular disease. , 1992, The New England journal of medicine.

[64]  J. Wilson,et al.  Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. , 1991, Science.

[65]  J. Manson,et al.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.

[66]  I. Godsland,et al.  The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. , 1990, The New England journal of medicine.

[67]  C. Pepine,et al.  Blood pressure lowering in patients with diabetes—one level might not fit all , 2011, Nature Reviews Cardiology.

[68]  M. Fisher Heart Disease and Diabetes , 2009 .

[69]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[70]  W. J. Howard Low-Fat Dietary Pattern and Risk of Cardiovascular Disease: The Women's Health Initiative Randomized Controlled Dietary Modification Trial , 2007 .

[71]  R. Krauss Clinical trials report , 2007 .

[72]  M. Roizen Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-analysis of Randomized Controlled Trials , 2007 .

[73]  V. Pinn,et al.  Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. , 2007, Circulation.

[74]  A. Rabinstein A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women , 2006 .

[75]  Anne L. Taylor,et al.  Evidence-based guidelines for cardiovascular disease prevention in women. , 2004, Journal of the American College of Cardiology.

[76]  Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. , 2002, American family physician.

[77]  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2002, Circulation.

[78]  S. Oparil,et al.  Guide to Preventive Cardiology for Women.AHA/ACC Scientific Statement Consensus panel statement. , 1999, Circulation.

[79]  R. Weinshilboum,et al.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.

[80]  D R Jacobs,et al.  High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. , 1990, American journal of epidemiology.